 |
Prospector
Profile
225-04
|
| |
| Interpharm Holdings, Inc. |
NAICS |
325412 |
| 75 Adams Avenue
Hauppauge, NY 11788 |
Description |
Pharmaceuticals Mfg. |
| (631) 952-0214 |
Employees |
670 |
| http://www.interpharminc.com |
Revenue |
(mil) |
75.5900 |
| |
Income |
(mil) |
-14.0600 |
| |
Assets |
(mil) |
74.3700 |
| |
Liability |
(mil) |
62.9600 |
| |
(for the year ended ) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Interpharm Holdings Inc.'s consolidated balance sheet at December 31, 2007, showed $64.3 million in total assets, $53.1 million in total liabilities, and $16.5 million in redeemable convertible preferred stock, resulting in a $5.3 million total stockholders' deficit. At December 31, 2007, the company's consolidated balance sheet also showed strained liquidity with $27.4 million in total current assets available to pay $44.0 million in total current liabilities. The company reported a net loss of $10.9 million on net sales of $16.2 million for the second quarter ended December 31, 2007, compared with a net loss of $4.1 million on net sales of $17.5 million in the same period ended December 31, 2006.
|
| |
|
Intellectual Property:
Interpharm owns the registered trademark REPRAXIN. [SEC Filing 10-K 11-15-07]
|
| |
|
Description:
Interpharm Holdings, through its subsidiary, Interpharm, Inc., engages in the development, manufacture, and marketing of generic prescription strength and over-the-counter pharmaceuticals in the United States.
|
| |
|
Officers:
Dr. Maganlal K. Sutaria (Chair); Cameron Reid (CEO); Peter Giallorenzo (EVP, COO & CFO); Kenneth Cappel (EVP & Gen. Counsel); Raj Sutaria (EVP); Jeffrey Weiss (EVP); Jonathan Berlent (SVP); David Reback (Dir.); Stewart Benjamin (Dir.); Kennith Johnson (Dir.); Richard J. Miller (Dir.); Joan P. Neuscheler (Dir.)
|
| |
|
Auditor:
Marcum & Kliegman LLP
|
| |
|
Securities:
Common stock symbol IPA; AMEX;
|
| |
| |
| |
| return to main page |
|
|
